LC-MS/MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-01. Numbers and descriptions here follow the published literature rather than marketing material.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
In 1979, Bakker and PTL came under investigation by the Federal Communications Commission (FCC) for allegedly misusing funds raised on the air. The FCC report was finalized in 1982 and found that Bakker had raised $350,000 that he told viewers would go towards funding overseas missions but that was actually used to pay for part of Heritage USA. The report also found that the Bakkers used PTL funds for personal expenses. FCC commissioners voted four to three to drop the investigation, after which they allowed Bakker to sell the only TV station that he owned, therefore bypassing future FCC oversight. The FCC forwarded its report to the U.S. Department of Justice, which declined to press charges, citing insufficient evidence. Bakker used the controversy to raise more funds from his audience, branding the investigation a "witch-hunt" and asking viewers to "give the Devil a black eye". A confidential 1985 Internal Revenue Service (IRS) report found that $1.3 million in ministry funds was used for the Bakkers' personal benefit from 1980 to 1983. The report recommended that PTL be stripped of its tax-exempt status, but no action was taken until after the Jessica Hahn scandal broke in 1987. Art Harris and Michael Isikoff wrote in The Washington Post that politics may have played a role in the three government agencies taking no action against PTL despite the evidence against them, as members of the Reagan administration were not eager to go after television ministers whose evangelical followers made up their base.
=== Popular opposition and regional rebellions === Research suggests that protests spur coups, as they help elites within the state apparatus to coordinate coups. A 2019 study found that regional rebellions made coups by the military more likely.
=== Entry into the cytoplasm === Ricin B chain binds complex carbohydrates on the surface of eukaryotic cells containing either terminal N-acetylgalactosamine or beta-1,4-linked galactose residues. In addition, the mannose-type glycans of ricin are able to bind to cells that express mannose receptors. RTB has been shown to bind to the cell surface on the order of 106–108 ricin molecules per cell surface. The profuse binding of ricin to surface membranes allows internalization with all types of membrane invaginations. The holotoxin can be taken up by clathrin-coated pits, as well as by clathrin-independent pathways including caveolae and macropinocytosis. Intracellular vesicles shuttle ricin to endosomes that are delivered to the Golgi apparatus. The active acidification of endosomes is thought to have little effect on the functional properties of ricin. Because ricin is stable over a wide pH range, degradation in endosomes or lysosomes offers little or no protection against ricin. Ricin molecules are thought to follow retrograde transport via early endosomes, the trans-Golgi network, and the Golgi to enter the lumen of the endoplasmic reticulum (ER). For ricin to function cytotoxically, RTA must be reductively cleaved from RTB to release a steric block of the RTA active site. This process is catalysed by the protein PDI (protein disulphide isomerase) that resides in the lumen of the ER. Free RTA in the ER lumen then partially unfolds and partially buries into the ER membrane, where it is thought to mimic a misfolded membrane-associated protein.
== Synthesis == The process used to create DBNPA is acid-catalyzed bromination of 3-cyanoacetamide. Polyethylene glycol is often used as the solvent due to its ability to dissolve both reactants and products effectively. Next, the bromination step is initiated by introducing bromine (Br2) or an alternative brominating agent, such as sodium bromide (NaBr) with an oxidant. DBNPA is formed as a result of an electrophilic bromination reaction at the α-carbon of 3-cyanoacetamide. Isolation and purification of DBNPA are carried out after bromination. The reaction mixture is neutralized, and the product is extracted and purified. The next step is drying, which yields DBNPA in its stable crystalline form. Usually, the reaction temperature is kept between 10 and 20 °C to minimize unintended side reactions. The concentration of bromine is carefully controlled, because an excess can lead to the formation of undesired byproducts that reduces the overall yield. The stability of DBNPA depends on the storage conditions. Due to its incompatibility with metals, DBNPA should be stored in non-metal containers. It must also be stored away from UV exposure, as this can degrade DBNPA.
Sources: en.wikipedia.org
Sadat became increasingly wary of Libya's radical direction, and the September 1973 deadline for implementing the Federation passed with no action taken. After the 1969 coup, representatives of the Four Powers—France, the UK, the US, and the Soviet Union—were called to meet RCC representatives. The UK and the US quickly extended diplomatic recognition, hoping to secure their military bases and fearing further instability. Hoping to ingratiate themselves with Gaddafi, in 1970 the US informed him of at least one planned counter-coup. Such attempts to form a working relationship with the RCC failed; Gaddafi was determined to reassert national sovereignty and expunge what he described as foreign colonial and imperialist influences. His administration insisted that the US and the UK remove their military bases from Libya. The British left in March and the Americans in June 1970. Moving to reduce Italian influence, in October 1970 all Italian-owned assets were expropriated, and the 12,000-strong Italian community was expelled alongside the smaller community of Libyan Jews. The day became a national holiday known as "Vengeance Day". Italy complained that this was in contravention of the 1956 Italo-Libyan Treaty, although no UN sanctions came. Aiming to reduce NATO power in the Mediterranean, in 1971 Libya requested that Malta cease allowing NATO to use its land for a military base, in turn offering Malta foreign aid. Compromising, Malta's government continued allowing NATO to use the island, but only on the condition that NATO would not use it for attacks on Arab territory.
== Awards and recognition == 1997: Newcomb Cleveland Prize 1998: W. Alden Spencer Award 1999: Albert Lasker Basic Medical Research Award 2000: Rosenstiel Award 2001: Gairdner Foundation International Award 2003: Louisa Gross Horwitz Prize 2003: Nobel Prize in Chemistry
In some countries, ayahuasca is a forbidden or controlled or regulated substance, while in other countries it is not a controlled substance or its production, consumption, and sale, is allowed to various degrees.
Sources: en.wikipedia.org
=== Potency === For equianalgesic dosing, when used sublingually, the potency of buprenorphine is about 40 to 70 times more potent than morphine. When used as a transdermal patch, the potency of buprenorphine may be 100 to 115 times greater than that of morphine.
=== United States === Under the Controlled Substances Act, dihydromorphine is listed as a Schedule I substance along with heroin. In the United States, its role in the production of dihydrocodeine and other related drugs make it a Schedule I substance with one of the higher annual manufacturing quotas granted by the US Drug Enforcement Administration: 3300 kilograms in 2013. Manufacturers, distributors, and importers with the correct DEA license and state permits related thereto are able to use Schedule I drugs in this fashion when they are transformed into something of a lower schedule. The DEA has assigned dihydromorphine and all of its salts, esters, etc. the ACSCN of 9145. As with nicomorphine, MDMA and heroin, dihydromorphine is also used in research in properly licensed facilities. US DEA Form 225, the most common and least expensive individual researcher's license, does not include Schedule I drugs, and so the lab must have a higher-level DEA registration. As with other licit opioids used for medical purposes in other countries, including even much weaker opioids like nicocodeine, benzylmorphine, and tilidine, the reason for dihydromorphine being in Schedule I is that it was not in medical use in the US at time the Controlled Substances Act of 1970 was drawn up.
The reaction has the important effect of converting the cofactor, nicotinamide adenine dinucleotide in its reduced form, into its oxidised counterpart NAD+. Isothermal titration calorimetry (ITR), nuclear magnetic resonance (NMR) crystallography, and clonal studies of OcDH and its substrates have led to the identification of the enzyme reaction mechanism. First, the Rossmann fold in Domain I of OcDH binds NADH. Binding of NADH to the Rossmann fold triggers small conformational change typical in the binding of NADH to most dehydrogenases resulting in an interaction between the pyrophosphate moiety of NADH with residue Arg324 on Domain II. This interaction with Arg324 generates and stabilizes the L-arginine binding site and triggers partial domain closure (reduction in the distance between the two domains). The binding of the guanidinium headgroup of L-arginine to the active site of the OcDH:NADH complex (located between the domains) induces a rotational movement of Domain II towards Domain I (via a helix-kink-helix structure in Domain II). This conformational change forms the pyruvate binding site. Binding of pyruvate to the OcDH:NADH:L-arginine complex places the alpha-ketogroup of pyruvate in proximity with the alpha-amino group of L-arginine. The juxtaposition of these groups on the substrates results in the formation of a Schiff base which is subsequently reduced to D-octopine. The priming of the pyruvate site for hydride transfer via a Schiff base through the sequential binding of NADH and L-arginine to OcDH prevents the reduction of pyruvate to lactate.
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.